Human papillomavirus DNA vaccine - Merck & Co.

Drug Profile

Human papillomavirus DNA vaccine - Merck & Co.

Alternative Names: HPV DNA vaccine - Merck & Co.

Latest Information Update: 05 Oct 2006

Price : $50

At a glance

  • Originator Merck & Co
  • Class Cancer vaccines; DNA vaccines; Gene therapies; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Human papillomavirus infections

Most Recent Events

  • 05 Oct 2006 No development reported - Preclinical for Human papillomavirus infections in USA (unspecified route)
  • 05 Sep 2003 Vical has reacquired the rights to apply its core vaccine technology for HPV previously licensed to Merck & Co
  • 20 Aug 2002 This vaccine is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top